Gennaro Marco Falco

Mi occupo quotidianamente della prevenzione, diagnosi precoce e gestione dei tumori cutanei, effettuando con scrupolo la mappatura dei nevi e mi occupo con dedizione alla diagnosi e cura delle patologie infiammatorie della cute come la psoriasi, la dermatite atopica, la dermatite seborroica, l'acne, la rosacea nonchè delle patologie degli annessi cutanei (capelli e unghie). 

• Specializzazione in Dermatologia e Venereologia 50/50 e lode, Università Cattolica del Sacro Cuore
• Fellowship Ospedale Pediatrico Bambino Gesù Campi di studio: Dermatologia Pediatrica
• Laurea Magistrale in Medicina e Chirurgia 110/110 con lode, Università Cattolica del Sacro Cuore
• Diploma di Scuola Superiore 100/100 Liceo Classico Marco Galdi, Cava de Tirreni 

• Medico in formazione specialistica n Dermatologia e Venereologia 50/50 e lode, Università Cattolica del Sacro Cuore (2021-2025)
• Fellowship Ospedale Pediatrico Bambino Gesù Campi di studio: Dermatologia Pediatrica (2024) 

• Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study. Eur Acad Dermatol Venereol
  Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study. The Journal of Dermatology
• Journey of Patients with Psoriasis in an Italian Tertiary Centre, an 11-year Retrospective Analysis. Acta Dermato-Venereologica
  Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies. International Journal of Dermatology
• Long-Term Real-World Safety Profile of Secukinumab Assessed Through a 9-Year. Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study. Dermatologic Therapy
• Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab. Skin Health and Disease
• Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literature. Drugs in Context
• Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study. Journal of Dermatological Treatment
• Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients. International Journal of Dermatology
• Paradoxical skin reaction to certolizumab, an overlap of neutrophilic dermatoses. JDDG
• Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled. Frontiers in Medicine
• Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a "real-world", mono-center experience.
• Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis.